

## Attachment A

### **The claims as they should appear after entry of the amendments**

1. An intranasal, transdermal, or intradermal dose form comprising 0.5 ng to 20 µg desmopressin and a pharmaceutically acceptable carrier which when administered to a patient in accordance with packaged instructions establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per ml plasma/serum to about a maximum of 10.0 picograms desmopressin per ml plasma/serum and decreases urine production.
3. The dose form of claim 1 comprising from about 0.05 µg to about 10 µg desmopressin.
4. The dose form of claim 1 comprising from about 0.1 µg to about 2 µg desmopressin.
6. The dose form of claim 1 for application to the skin comprising a patch, gel, cream, ointment, or iontophore.
7. The dose form of claim 1 for application to the skin comprising a an intradermal patch.
9. The dose form of claim 1 which establishes in a patient a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per ml plasma/serum to about 5.0 picograms desmopressin per ml plasma/serum.
27. An intranasal dose form comprising desmopressin and a pharmaceutically acceptable carrier which when administered intranasally to a patient in accordance with packaged instructions establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per ml plasma/serum to about a maximum of 10.0 picograms desmopressin per ml plasma/serum for a time between four and six hours and decreases urine production.

28. The dose form of claim 27 which establishes in a patient a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per ml plasma/serum to about 5.0 picograms desmopressin per ml plasma/serum.

29. An intradermal or transdermal pharmaceutical dose form comprising desmopressin and a pharmaceutically acceptable carrier which when administered intradermally or transdermally to a patient establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per ml plasma/serum to about a maximum of 10.0 picograms desmopressin per ml plasma/serum for a time between four and six hours and decreases urine production.

30. The dose form of claim 29 which establishes a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per ml plasma/serum to about 5.0 picograms desmopressin per ml plasma/serum.

31. The dose form of claim 29 comprising between 0.05 µg and 10 µg desmopressin.

32. The dose form of claim 29 comprising an intradermal a patch.

33. The dose form of claim 29 comprising a patch, gel, cream, ointment, or iontophore.

LIBC/3507219.1